MREO Stock Forecast & Price Target

Mereo BioPharma Group is attractive because alvelestat targets a major unmet need in severe AATD-related lung disease, where liver-directed antisense approaches do not address progressive lung damage driven by unopposed neutrophil elastase. The asset has already shown meaningful efficacy signals, including a 48% reduction in moderate/severe exacerbations and a 36% reduction in annualized exacerbation rate across ATLANTa and ASTRAEUS by 16wk, while also securing European Orphan Designation and a Sentynl option agreement. Financially, the deal could fund advancement with $40M for development costs, up to $435M in milestones, and double-digit U.S. royalties, supporting late-stage execution alongside ongoing setrusumab regulatory discussions.

Mereo BioPharma Group is fundamentally pressured by a persistent funding gap, as it will require additional capital to advance its clinical candidates and there is no assurance that financing, milestone receipts from Ultragenyx, or new partnering deals will be secured on favorable terms. Its lead assets still face material development and commercialization risk, with alvelestat dependent on clinical success in a difficult rare-disease setting where lung damage from AATD remains severe despite broader progress in the field. The stock also carries standard biotech downside from uncertain clinical readouts, regulatory hurdles, and price-sensitive markets, making the company’s value highly contingent on outcomes rather than current financial strength.